Multiple animal studies for medical chemical defense program in soldier/patient decontamination and drug development on task 85-18: Conduct of pralidoxime chloride, atropine in citrate buffer and pyridostigmine bromide pharmacokinetic studies, and comparative evaluation of the efficacy of pyridostigmine plus atropine. Final report, June 1985-August 1988
This study was conducted to evaluate the efficacy of the reversible acetylcholinesterase inhibitor, pyridostigmine bromide, as an addition to standard therapy with atropine pralidoxime bromide, as an addition to standard therapy with atropine and pralidoxime chloride (2-PM), against the acute lethal effects of Soman, GD, using a primate model (male, Rhesus monkey). In addition, the pharmacokinetics of pyridostigmine bromide (intragastric), atropine (intramuscular), and 2-PAM (intramuscular) were individually examined in the primate model using three different dose levels for each compound. In the efficacy study, the combined prophylactic/post/challenge therapy regimen resulted in survival following an intramuscular challenge dose as high as 617 micrograms/kg in contrast to an estimated, unprotected, median lethal GD dose (LD50) of 15.3 micrograms/kg for the same animals.
- Research Organization:
- Battelle Columbus Labs., OH (United States)
- OSTI ID:
- 6957270
- Report Number(s):
- AD-B-127309/3/XAB; CNN: DAMD17-83-C-3129
- Country of Publication:
- United States
- Language:
- English
Similar Records
Multiple animal studies for medical chemical defense program in soldier/patient decontamination and drug development. Task 85-18. Appendix K-1. Documentation of GD administration and dose verification. Final report, June 1985-August 1988
Multiple animal studies for medical chemical defense program in soldier/patient decontamination and drug development. Task 85-18. Appendix A. Protocol, amendments and deviations. Final report, June 1985-August 1988